wow, snow-making machines depend on this bacterial protein to nucleate ice
thank you P syringae for enabling snowboarding on the East coast
https://t.co/xljL0j5eAW
https://t.co/Hu4TOONrH4
Our first pre-print is live! We harness the power of voltage-controlled electrolysis by developing Shono-type amination. Electroanalytical tools guide selective oxidation of substrate over nucleophile, enabling predictable and modular C–N bond formation.
https://t.co/8D0YPvQWG7
Next chapter in our hypervalent adventure! how would you access polyhalogenated biaryls in a perfectly selective way? Great collaboration with @Merck @chair_itn! congratulations to @danielcarter_96 Maxime et @PascalHauk https://t.co/hXs1IKJXae
Out now in Science, my first co-first author paper! Proud to have worked so hard with this team. Photochemical logic was instrumental in accessing these unique polyhalogenated targets!
https://t.co/o2FUm0JzWb
Shuttle HAT: A simple solution for all your MHAT needs. No more wasting silanes and/or oxidants to generate your Co–H – Now all you need is a C–H bond.
https://t.co/TG5LVgCrnZ
#TotalSynthesis of Psammaplysins A, M, O, and Q and Ceratinamide A by Andrew P. Morrow and Myles W. Smith at @UTSWNews in @J_A_C_S https://t.co/7vm5TcaiKN
The Division of Organic Chemistry is encouraging undergraduate students to apply for a 2024 Summer Undergraduate Research Fellowship (SURF). Applications are due by February 14th. Instructions can be found on the SURF page of our website. Please share!
https://t.co/qyHtPspIPr
Used paperclips with a class today to show how a catalyst acts as a surface for reactants to come together and form a product. Based on an old magic trick, I got this idea from Paul Nugent from @SonS_Ireland. The ending is a nice surprise for students!
This is a great demo of pi-pi stacking interactions, a crystalline solid from 2 liquids (hexafluorobenzene mixed with mesitylene) https://t.co/X8da60Z58i
2023 Small Molecule Approvals! @drughuntersite
A lot of fascinating firsts in 2023 including:
-The first FDA-approved oral ER degrader
-The first FDA-approved reversible BTK inhibitor
-The first FDA-approved gamma-secretase inhibitor (not in Alzheimer’s!)
-A reversible covalent, brain-penetrant Nrf2 activator
-The first drug derived from mRNA display screening for macrocyclic peptides
-The first PI3K inhibitor with a first approval outside oncology
-A factor B-targeting Breakthrough Therapy for paroxysmal nocturnal hemoglobinuria
-The first intranasal CGRP antagonist for fast-acting migraine treatment
Full Open Access article + hi-res poster here:
https://t.co/Q3rXkwMBp9